The nation of Zimbabwe has rejected a substantial US health deal valued at 367 million US dollars (£272m) over five years over Washington's demand for sensitive biological samples.
This rejection came to light after a internal memorandum dated December was disclosed, indicating that Head of State Emmerson Mnangagwa believed the agreement was "lopsided".
A government spokesman later clarified that the US was demanding access to health data for research and profit while refused to share the resulting advantages from future vaccines.
"We must now begin the difficult and regrettable process of ending our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had provided more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for more dialogue to reach a agreement agreeable to all parties so the country's critical HIV treatment initiative can be sustained.
Wider Background
Zimbabwe's decision comes after a comparable case in Kenya, where a high court suspended a similar deal with the US following concerns were raised about the safety of citizens' medical information.
After returning to office recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
The agency had managed assistance for the US government, but Trump stated its expenditure was "inefficient" and his government was seeking direct bilateral deals to enhance transparency and accountability.
As per statements, 16 nations in Africa have to date agreed to similar health pacts, constituting more than $18.3bn in committed funds.
Details of the Declined Deal
The money for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this collaboration would have delivered significant benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on HIV treatment through American-funded initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana said the proposed deal was "unfair".
"The proposal required Zimbabwe to surrender its biological resources and data for a long time, without any equivalent guarantee of access to any scientific breakthroughs – such as new medicines or tests – that could be developed from that shared data," Mangwana explained.
"In essence, our country would supply the raw materials for medical research with no certainty that the final treatments would be available to our citizens if a future disease outbreak emerge."
Sovereignty and Global Health
He also said that the US's withdrawal from the global health body and its pursuit of bilateral deals were upending frameworks already set up through the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing system designed to manage potential global health emergencies.
"This mechanism is intended to guarantee that when a country contributes its samples, the benefits – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the capability to create them."
The government's concerns regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We are open to further dialogue with our American counterparts on how future co-operation might be structured in a manner that honours the sovereignty and interests of both nations."
Health Experts Response
A leading public health body stated it acknowledged the government's concerns, but suggested that talks must proceed given that a large portion of the country's HIV programmes depended on external financing.
"Where specific concerns arise, including those involving information security or implementation frameworks, these can frequently be resolved through detailed discussion and mutually agreed protections," the group commented.
The situation underscores the ongoing tensions between accepting much-needed foreign assistance and safeguarding national sovereignty in an increasingly data-driven world.